Aprea Therapeutics (APRE) AI Stock Analysis

• Market Cap: $9.24M
• Dividend Yield: N/A
• Average Volume (3M): 23.88K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.63
• Revenue Growth: 157.63%
• EPS Growth: 40.52%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.66
• Shares Outstanding: 5,531,373
• 10 Day Avg. Volume: 37,518
• 30 Day Avg. Volume: 23,884
• PEG Ratio: -0.06
• Price to Book (P/B): 0.64
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.85
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $10.00
• Price Target Upside: 498.80% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 40 Underperform
• Price Target: ―

Aprea Therapeutics receives a low overall score due to significant financial challenges, including consistent losses and lack of revenue generation. The company's strong balance sheet is a positive but is offset by negative cash flows and a reliance on external financing. Technical indicators suggest a bearish trend, and the valuation is unattractive due to a negative P/E ratio and no dividend yield.

Positive Factors

Clinical Development

Aprea's ATRN-119 is the first in the macrocyclic ATRi class to move into the clinic, potentially leading to success where others have stumbled.

Safety Profile

The safety profile for ATRN-119 continues to be favorable, which is a departure from other ATRi drugs in development that faced toxicity issues.

Negative Factors

Earnings

Aprea announced 3Q24 results, posting EPS of ($0.64) compared with analyst estimate of ($0.62) and consensus of ($0.74).

Macro Market Factors

APRE shares have pulled back significantly mainly from challenging macro market factors, particularly for microcap biotech.

Aprea Therapeutics Business Overview & Revenue Model

Company Description

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

How the Company Makes Money

Aprea Therapeutics makes money through the development and commercialization of its proprietary cancer therapeutics. The company generates revenue mainly from partnerships and collaborations with larger pharmaceutical companies, which may include license agreements, milestone payments, and royalties from the commercialization of its drug candidates. Aprea also seeks funding through grants and research collaborations to support its ongoing research and development efforts. Furthermore, successful clinical trials leading to market approval of its products can significantly increase its revenue through direct sales and licensing deals.

Aprea Therapeutics Financial Statement Overview

Summary

Overall, Aprea Therapeutics faces significant financial challenges with no meaningful revenue generation and consistent losses. The strong balance sheet with no debt provides some stability, but negative cash flows and lack of profitability present ongoing risks. The company is heavily reliant on external financing to support operations.

Income Statement

Aprea Therapeutics has faced significant challenges in generating revenue, with no revenue reported in recent years except for a minimal amount in 2023. The company has consistently reported negative net income, indicating ongoing losses. Margins such as gross profit, EBIT, and EBITDA are not meaningful due to negligible or zero revenue, highlighting the company's struggle to achieve profitability.

Balance Sheet

The company maintains a strong equity position with no debt, resulting in a debt-to-equity ratio of zero. However, the return on equity (ROE) is negative due to consistent losses. The equity ratio is favorable, indicating a healthy balance between equity and total assets. Despite these strengths, the lack of revenue and profitability remains a concern.

Cash Flow

Aprea Therapeutics has negative operating and free cash flows, reflecting cash burn typical of biotech firms in development phases. The operating cash flow to net income ratio is negative due to losses, and free cash flow growth is also negative. While financing activities have provided cash inflows, the company’s cash flow position remains weak.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
956.22K	0.00	583.23K	0.00	0.00	0.00
	Gross Profit
939.77K	0.00	576.18K	-186.44K	-271.68K	-229.61K
	EBIT
-14.77M	-14.32M	-15.47M	38.18M	-38.04M	-52.15M
	EBITDA
-14.52M	-14.32M	-14.28M	-112.48M	-36.86M	-53.25M
	Net Income Common Stockholders
-13.51M	-12.96M	-14.29M	-224.88M	-36.54M	-53.92M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
65.68M	22.85M	21.61M	28.79M	53.08M	89.02M
	Total Assets
66.02M	23.98M	22.65M	30.16M	56.82M	92.81M
	Total Debt
0.00	0.00	0.00	0.00	190.47K	335.16K
	Net Debt
-65.68M	-22.85M	-21.61M	-28.79M	-52.89M	-88.68M
	Total Liabilities
117.46M	4.67M	5.70M	4.51M	7.32M	15.41M
	Stockholders Equity
-51.44M	19.31M	18.26M	25.64M	49.51M	77.40M
Cash Flow		Free Cash Flow
-6.41M	-13.57M	-12.27M	-25.01M	-37.69M	-41.83M
	Operating Cash Flow
-13.81M	-13.56M	-12.18M	-25.01M	-37.69M	-41.80M
	Investing Cash Flow
―	-15.48K	-93.09K	0.00	0.00	-25.71K
	Financing Cash Flow
14.58M	14.82M	5.14M	682.97K	1.75M	150.95K

Aprea Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.67
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APRE, the sentiment is Neutral. The current price of 1.67 is below the 20-day moving average (MA) of 1.70, below the 50-day MA of 1.80, and below the 200-day MA of 2.94, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 49.78 is Neutral, neither overbought nor oversold. The STOCH value of 41.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for APRE.

Aprea Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KPRX	56 Neutral	$9.31M	4.67	-41.13%	―	―	―
Sector *	53 Neutral	$5.14B	3.23	-45.01%	2.85%	17.55%	-0.69%
DWTX	49 Neutral	$10.01M	―	-451.34%	―	―	-57.84%
EVAX	46 Neutral	$11.88M	―	467.86%	―	4455.07%	77.31%
APRE	40 Underperform	$9.24M	―	-59.80%	―	157.63%	40.52%
ACXP	39 Underperform	$9.39M	―	-285.79%	―	―	23.65%
CARM	27 Underperform	$7.73M	―	-362.79%	―	32.45%	39.31%

Aprea Therapeutics Corporate Events

Aprea Therapeutics Reports Promising Results for APR-1051 Trials

Aprea Therapeutics has announced promising preliminary safety results for its WEE1 inhibitor, APR-1051, showcased at an international oncology conference. The Phase 1 trial indicates APR-1051 is safe and well-tolerated without serious side effects, presenting potential as a treatment for advanced solid tumors. With ongoing trials in the U.S., the company is optimistic about further exploring APR-1051’s therapeutic potential, aiming for more efficacy data in 2025.